cost-effectiveness of ranibizumab for neovascular age-related macular degeneration成本效益之初的新生血管性年龄相关性黄斑变性.pdfVIP

  • 2
  • 0
  • 约7.12万字
  • 约 11页
  • 2017-09-06 发布于上海
  • 举报

cost-effectiveness of ranibizumab for neovascular age-related macular degeneration成本效益之初的新生血管性年龄相关性黄斑变性.pdf

cost-effectiveness of ranibizumab for neovascular age-related macular degeneration成本效益之初的新生血管性年龄相关性黄斑变性

Cost Effectiveness and Resource Allocation BioMed Central Research Open Access Cost-effectiveness of ranibizumab for neovascular age-related macular degeneration 1,2,3 1 4 Susan F Hurley* , Jane P Matthews and Robyn H Guymer

您可能关注的文档

文档评论(0)

1亿VIP精品文档

相关文档